Compare Recursion Pharmaceuticals Inc (RXRX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: Sibanye Stillwater Ltd is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Sibanye Stillwater Ltd for 51 Days on average.
| RXRX | SBSW | |
|---|---|---|
Market Cap | $2.14B | $6.88B |
Volume | 30,789,535 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $21.12 |
52-Week Low | $2.84 | $8.00 |
Typical Hold Time | 23 Days | 51 Days |
Enterprise Value | $1.66B | $7.78B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
SBSW trades at $9.91, up 2.38% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% EBITDA increase, driving positive sentiment.
The outlook is mixed: analyst consensus is a 'Buy' with a $14.25 price target, implying 44% upside, supported by operational improvements and commodity price strength. Risks include volatile earnings, high debt levels, and exposure to commodity cycles. Upside hinges on sustained execution of the growth roadmap and cost discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
